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ABSTRACT 
   Most genetic studies in colorectal carcinomas have focused on those 
abnormalities that are acquired by primary tumours, particularly in the transition from 
adenoma to carcinoma, while few studies have compared the genetic abnormalities of 
primary versus paired metastatic samples. In this study we used high-density 500K 
single-nucleotide polymorphism arrays to map the overall genetic changes present in 
liver metastases (n=20) from untreated colorectal carcinoma patients studied at 
diagnosis versus their paired primary tumours (n=20). MLH1, MSH2 and MSH6 gene 
expression was measured in parallel by immunohistochemistry. Overall, metastatic 
tumours systematically contained those genetic abnormalities observed in the primary 
tumour sample from the same subject. However, liver metastases from many cases (up 
to eight out of twenty) showed acquisition of genetic aberrations that were not found in 
their paired primary tumors. These new metastatic aberrations mainly consisted of 1) an 
increased frequency of genetic lesions of chromosomes that have been associated with 
metastatic colorectal carcinoma (1p, 7p, 8q, 13q, 17p, 18q, 20q) and, more interestingly, 
2) acquisition of new chromosomal abnormalities (e.g. losses of chromosomes 4 and 
10q and gains of chromosomes 5p and 6p). These genetic changes acquired by 
metastatic tumours may be associated with either the metastatic process and/or adaption 
of metastatic cells to the liver microenvironment. Further studies in larger series of 
patients are necessary to dissect the specific role of each of the altered genes and 
chromosomal regions in the metastatic spread of colorectal tumours. 
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INTRODUCTION 
  Occurrence of distant metastasis in sporadic colorectal cancer (e.g.: liver 
metastasis) confers a poor prognosis. In fact, metastatic disease is the main cause of 
death in colorectal carcinoma patients, and the liver is the most common site for 
metastatic spread of colorectal carcinoma.1,2 Current knowledge about the genetic 
pathways of clonal evolution in colorectal carcinoma, suggest that development of 
colorectal cancer could be triggered by the clonal expansion of cells that carry 
mutations which most frequently involve the APC, RAS, TP53 and/or DCC genes and 
lead to a growth and/or survival advantage of tumour cells.3 As metastatic cells derive 
from primary tumour cells, specific genomic alterations driving these ultimate steps of 
the metastatic cascade are expected to be acquired over the genomic profile of 
neoplastic cells from the primary tumour.4 The genomic abnormalities which are 
potentially characteristic of such advanced stages of the disease are complex and so far, 
poorly described and partially understood. This relates to the fact that most genetic 
studies in colorectal cancer have focused on those abnormalities that are acquired in 
primary tumours particularly in the transition from adenoma to carcinoma, and few 
studies have compared these abnormalities with those observed in paired metastatic 
samples.5-7 Despite this, multiple recurrent chromosomal abnormalities which are found 
in primary tumours have been associated with metastatic colorectal carcinoma. Among 
others, these mainly include numerical changes such as gains of chromosomes 8q, 13q 
and 20q and losses of the 1p, 8p, 17p and 18q chromosomal regions.8-10 However, the 
molecular mechanisms underlying the association of such genetic profiles with 
metastatic colorectal carcinoma remain largely unknown.  
 Previous studies using conventional karyotyping,5 comparative genomic 
hybridization (CGH),5,7,11 fluorescence in situ hybridization (FISH)9,11 or microsatellite 
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markers to detect regions of loss of heterozygosity (LOH),12 have largely failed in 
identifying recurrent chromosomal abnormalities acquired in metastatic vs. primary 
colorectal tumours. This could be explained at least in part, because of the relatively 
limited resolution of these techniques. More recently, the availability of high-density 
single nucleotide polymorphism (SNP)-arrays has facilitated the identification of small 
regions of chromosomal gains and losses because of its higher resolution (down to 2.5 
kb)13 and provides new opportunities in the identification of novel cancer genes 
involved in the metastatic process of colorectal cancer. However, previous reports in 
which high-density SNP-arrays have been used to investigate the genetic profiles of 
colorectal carcinoma have specifically focused on primary tumour samples14 and to the 
best of our knowledge, no study has been reported so far in which high-density SNP-
arrays are employed to investigate the potential genetic differences between paired 
primary and metastatic tumours from colorectal carcinoma patients.  
In the present study, we applied high-density (500K) SNP mapping arrays -mean 
distance between the interrogated SNPs of 5.8 kb (median intermarker distance of 2.5 
kb)- to map the overall genetic changes present in  liver metastases from 20 untreated 
colorectal carcinoma patients studied at diagnosis versus their paired primary tumours 
(n=40 samples). Our goal was to search for recurrent genetic differences between paired 
primary vs metastatic tumour samples that might contain candidate genes highly 
characteristic of metastatic liver disease.  
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MATERIALS AND METHODS 
 Patients and samples. Tissue specimens from 20 sporadic colorectal 
adenocarcinomas and 20 paired liver metastases (n=40 samples) were obtained from 20 
patients (13 males and 7 females; median age of 70 years, ranging from 49 to 80 years) 
after informed consent had been given by each subject. It should be noted that only 
patients with metastatic lesions able to be resected were included in this cohort, which 
therefore is not representative of the whole colorectal cancer patient population. All 
patients underwent surgical resection of both tumour tissues at the Department of 
Surgery of the University Hospital of Salamanca (Salamanca, Spain). All tumours were 
diagnosed and classified according to the WHO criteria15 and they were all studied prior 
to any treatment was given. According to tumour grade, 11 cases were classified as 
well-differentiated tumours, 8 as moderately- and one as poorly-differentiated 
carcinomas. In all cases, histopathological grade was confirmed in a second independent 
evaluation by an experienced pathologist. Median follow-up at the moment of closing 
the study was of 37 months (range: 36-96 months). The study was approved by the local 
ethics committee of the University Hospital of Salamanca (Salamanca, Spain). 
Seven primary tumours were localized in the rectum and the other 13 either in 
the right (caecum, ascending or transverse) or the left (descending and sigmoid) colon. 
The mean size of primary tumours was of 5.3 ± 1.9 cm with the following distribution 
according to their TNM stage at diagnosis:16 T3N0M0, 2 cases; T3N1M1, 4; T3N1M0, 
4; T3N2M1, 4; T4N0M1, 1; T4N0M0, 3; T4N1M1, 1 and; T4N2M1, 1 case. Liver 
metastases were identified either at the time of colorectal surgery (n= 11) or during the 
first year after initial diagnosis (n=9); to date patients have not shown any other 
metastasis. The mean size of liver metastases was of 4.3 ± 2.2 cm. 
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After histopathological diagnosis was established, part of the primary tumour 
and its paired liver metastasis (both corresponding to a macroscopically tumoral region) 
were used to prepare single-cell suspensions. Once prepared, single cell suspensions 
were resuspended in methanol/acetic (3/1; vol/vol) and stored at -20ºC for further 
interphase FISH analyses, as recently described.17 The remaining tissue was either fixed 
in formalin and embedded in paraffin, or frozen in liquid nitrogen and stored at room 
temperature or at -80 °C, respectively. All tissues were evaluated after haematoxylin-
eosin staining to confirm the presence of tumour cells and to evaluate their quantity in 
each individual sample. For SNP-array studies, tumour DNA was extracted from 
representative areas of freshly frozen tumour tissues (primary tumours and liver 
metastases), which contained ≥65% epithelial tumour cells localized mirror cut to those 
used for iFISH analyses. In turn, normal DNA was extracted from peripheral blood 
leukocytes from the same patient. For the three types of samples (primary tumors, 
paired liver metastases and peripheral blood leukocytes), DNA was extracted using the 
QIAamp DNA mini kit (Qiagen, Hilden, Germany) following the instructions of the 
manufacturer.  
SNP-array studies. Each DNA sample derived from primary tumours and liver 
metastases and normal peripheral blood leukocytes was hybridized to two different 
250K Affymetrix SNP Mapping arrays (NspI and StyI SNP arrays, Affymetrix, Santa 
Clara, CA); for this purpose 250 ng of DNA per array was used, according to the 
instructions of the manufacturer. Fluorescence signals were detected using the 
Affymetrix GeneChip Scanner 3000 (Affymetrix) and average genotyping call rates of 
94.4%, 91.5% and 97.3% were obtained for primary tumors, liver metastases and 
normal peripheral blood DNA samples, respectively.  
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In order to identify copy number changes throughout the whole tumour genome, 
the aroma.affymetrix algorithm was used, following the CRMA v2 method described 
elsewhere18 (R-software package, http://www.aroma-project.org) and the following 
sequential steps: i) calibration for crosstalks between pairs of allele probes; ii) 
normalization for probe nucleotide-sequence effects, and; iii) normalization for PCR 
fragment-length and probe localization effects. Then, data from the 250K StyI and 250K 
NspI arrays was integrated into a single database and raw copy number values were 
calculated as transformed log2 values of the primary tumour/normal peripheral blood, 
liver metastasis/normal peripheral blood, liver metastases/primary tumour ratios 
calculated for each individual patient. 
In order to identify DNA regions with similar copy number values we used 
Circular Binary Segmentation as implemented in the DNAcopy Bioconductor package19 
with the default parameters; a p-value ≤ 0.01 for ≥ 5 markers per DNA segment was 
used to define points with changes. We used the smoothed value by assigning the 
median segment value to each probe. For the identification of altered (gained or lost) 
DNA regions a threshold was established based on the changes observed in the 
fluorescence intensity of sequential DNA segments for primary tumour versus 
peripheral blood, liver metastasis versus peripheral blood and for liver metastases 
versus primary tumor samples, for each of the 20 patients studied. Log2 ratio values > 
0.09 and < -0.09 were used as cut-off thresholds to define the presence of increased and 
decreased copy number values, respectively. High-level gains (DNA amplification) 
were defined as regions with a mean log2 copy number ratio ≥0.25. The specific 
frequencies of both copy number gains and losses per SNP were established and plotted 
along individual chromosomes for each tumour sample analyzed, for all individual 
cases studied. Based on the empirical frequency distribution of gains and losses among 
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the 20 primary and the 20 metastatic tumor samples respectively, we took the common 
altered regions grouping the contiguous SNPs with adjusted p-values < 0.01 (False 
Discovery Rate correction based on the Benjamini and Hochberg procedure).20 Minimal 
common regions were defined as the smallest subset of SNPs in the altered regions with 
the highest frequency of gains and losses. At least 5 contiguous SNPs were required to 
define a region. Genes in these regions were identified using Ensembl release 53 
(http://www.ensembl.org). The pattern of copy number changes of the primary tumors 
here analyzed has been previously reported in detail in a recent study. 21 
Interphase fluorescence in situ hybridization (FISH) studies. In order to 
evaluate the reproducibility of the SNP-array results and to assess background noise 
impact of this technique, interphase FISH analyses of the same tumour samples was 
performed in parallel using 24 probes directed against an identical number of regions 
from 20 different human chromosomes, which are frequently altered in sporadic 
colorectal carcinomas. Overall, our results showed a high degree of correlation between 
both methods; this also holds true when such analysis was restricted to the most 
frequently altered regions, as previously described.21 
Immunohistochemistry. One block of formalin fixed paraffin wax embedded 
adenocarcinoma tissue was selected in each case. In all cases, this block comprised an 
area of normal colonic mucosa adjacent to the tumour. Sections (4 µm) were affixed to 
Superfrost plus slides (CML, Nemours, France) and dried overnight at 37°C. Paraffin 
was removed and the tissue rehydrated using xylene and ethanol. Slides were subjected 
to microwave antigen retrieval in 10 mM citrate buffer (pH 6) at 85ºC for 35 min and 
cooled in phosphate-buffered saline, pH 7.4 (Sigma). Endogenous peroxidase activity 
was blocked with 2% hydrogen peroxide in methanol and slides were washed with 
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phosphate-buffered saline prior to overnight incubation with the appropriate antibody at 
a dilution of 1:100. Commercially available monoclonal antibodies against the nuclear 
proteins MLH1 (Clone G168-15; BD Biosciences, San Jose, CA, USA), MSH2 (Clone 
FE11; Biocare Medical, CA, USA) and MSH6 (Clone BC/44; Biocare Medical) were 
applied, followed by staining with Strept ABC complex/HRP Duet kit (DAKO, 
Copenhagen, Denmark) in conjunction with diamino benzedene 180 mg in 300 ml 
phosphate-buffered saline with 300 ml hydrogen peroxide. Sections were washed under 
running tap water and then lightly counterstained in Mayer’s haematoxylin. Loss of 
expression was recorded when nuclear staining was absent from all malignant cells but 
preserved in normal epithelial and stroma cells. Two observers assessed all cases 
independently. 
Statistical methods. For all continuous variables, mean values and their 
standard deviation and range were calculated using the SPSS software package (SPSS 
12.0 Inc, Chicago, IL USA); for dichotomic variables, frequencies were reported. In 
order to evaluate the statistical significance of differences observed between groups, the 
Mann-Whitney U and the X2 tests were used for continuous and categorical variables, 
respectively (SPSS).  
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RESULTS 
Frequency and chromosomal localization of copy number changes in liver 
metastasis from colorectal carcinoma. Overall, liver metastases from the 20 colorectal 
cancer patients analyzed, systematically contained those chromosomal abnormalities 
that were identified in their paired primary colorectal carcinomas; (please note that the 
later have been previously described in detail for a larger series of patients).21 Despite 
this, some aberrations were either newly acquired or more frequently found in liver 
metastases than in their paired primary tumours, which could reflect an increased 
genetic instability of neoplastic cells from metastatic vs. primary tumor samples (Figure 
1).  
In detail, all liver metastases showed copy number changes in at least one 
chromosomal region. The highest frequency of copy number losses detected 
corresponded to chromosomes 1p (n=16; 80%), 17p (n=18; 90%) and 18q (n=19; 95%); 
in turn, copy number gains more frequently involved chromosomes 7p (n= 18; 90%), 8q 
(n=15; 75%), 13q (n=14; 70%) and 20q (n=15; 75%) (see Supplemental Table S1). 
Interestingly, each of these regions has been previously found to contain genes which 
are altered/involved in colorectal cancer (e.g.: ANGPT2, UBR5, KLF10, EIF3H, NOV, 
DCT, ABCC4, SLC15A1, EFNB2, IRS2, ING1, MAP2K4, ID1, BCL2L1, MYLK2, 
CBFA2T2 and E2F1) and/or genes that are relevant to the metastatic process (e.g.: 
ANGPT2, RRM2B, KLF10, RAD21, NOV, POU4F1, SPRY2, DCT, CLDN10, EFNB2, 
IRS2, COL4A2, ING1, MYH8,  MAP2K4, ID1, BCL2L1, TPX2, MYLK2 and E2F1) in 
addition to genes associated with other malignancies (i.e.: TRPS1, BTF3L1, DNAJC3, 
STK24, TM9SF2, LIG4, ARHGEF7, SCO1, MYOCD, GALR1, HCK and SMC1B) (Table 
1). From them, the ANGPT2, MAP2K4, E2F1, ID1 and BCL2L1 genes have been 
12 
 
reported to be involved in mechanisms that lead to increased cell proliferation and 
angiogenesis, and they have been found to be altered in both colorectal cancer and the 
metastatic events. 
Frequency and chromosomal localization of high-level copy number gains 
in liver metastases from colorectal carcinomas. Chromosome 7 showed 17 regions 
which displayed high level genetic amplification (Table 2) with mean log2 ratio 
fluorescence intensities of 0.28 (range: 0.25 to 0.36). These 17 regions were distributed 
along the whole chromosome 7 at the 7p22, 7p21, 7p15, 7p12, 7q22 and 7q36 
chromosome bands and they were all found to be altered (amplified) in ≥ 14/20 cases 
studied (70%) (see Supplemental Table S2). These regions contain multiple genes 
which have been recurrently associated with the pathogenesis of colorectal cancer and 
the metastatic process: FSCN1, TWIST1, ITGB8, DFNA5, HOXA7, GRB10, EGFR, 
AZGP1, MCM7, EPHB4 and MUC3A (Table 2). In turn, for chromosome 8 only two 
regions of high level genetic amplification (mean fluorescence intensities of 0.42 and 
0.37, respectively) were detected; both regions were localized at the 8q24 chromosome 
band, and they involved the MTSS1 and ASAP1 genes (Table 2). Additionally, 
chromosomes 13 and 20 also displayed three regions (two in chromosome 13 and one in 
chromosome 20) with high level genetic amplification (mean fluorescence intensities of 
0.45 and 0.43, respectively) containing genes potentially involved in the pathogenesis of 
colorectal cancer and the metastatic process, the KLF5, IRS2 and MMP9 genes coded in 
the 13q22.1, 13q34, and 20q13.12 chromosomal regions (Table 2). 
Acquired chromosomal abnormalities in liver metastases. In individual 
patients, primary tumors and their paired liver metastases frequently revealed the same 
chromosomal changes at both sites (Figure 1). However, liver metastases from eight out 
of twenty cases showed acquisition of new genetic abnormalities that were not found in 
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their paired primary tumors. These new metastatic aberrations included copy number 
gains at chromosomes 2p, 5p, 6p, 7q and 11p together with copy number losses of 
chromosomes 4, 5q and 10q (Table 3). The specific abnormalities which were 
recurrently detected in 8/20 colorectal carcinomas metastasis for those chromosomal 
regions that showed a normal diploid profile in their corresponding (paired) primary 
tumors, are shown in figure 2. As illustrated, these metastatic abnormalities involved 
chromosomal regions which harbor i) tumor suppressor genes that play a key role in the 
metastatic process (e.g.: the ANXA5, CCNA2, IL2 and IL21 genes at chromosome 4q27; 
the PLK4, IL15, GAB1, HHIP and SMAD1 genes coded at the 4q28.1 chromosome 
regions and the PTEN gene coded at the 10q23.33 chromosomal region) and; ii) 
oncogenes (e.g.: the PTGER4 and PRKAA1 genes coded at chromosome 5p13.1 and 
both the RIPK1 and NQO2 genes coded at chromosome 6p25.2); copy number gains of 
the former two oncogenes have been associated with advanced colorectal carcinoma. 
Many other genetic aberrations were present in liver metastases from colorectal 
carcinoma analyzed but at lower frequencies (Figure 1). 
Correlation between the chromosomal changes detected by interphase FISH 
and SNP-arrays studies. Overall, the chromosomal abnormalities identified by 
interphase FISH in liver metastases showed profiles similar to those found by SNP-
array studies, also when such analysis was restricted to the most frequently altered 
regions. Thus, gains/amplification at 7q were detected in 60% of the cases by interphase 
FISH versus 70% by SNP-arrays studies (r2=0.67; p<0.001); similarly, 
gains/amplification of chromosomes 8q (found in 70% of cases by interphase FISH 
versus 75% by SNP-arrays studies; r2= 0.79; p<0.001), 13q (80% versus 70%; r2=0.78; 
p<0.001) and 20q (80% versus 75%; r2=0.80; p<0.001) as well as deletions of 
chromosomes 8p (65% versus 70%; r2=0.81; p<0.001), 17p (75% versus 90%; r2=0.64; 
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p=0.02) and 18q (75% versus 95%; r2=0.63; p=0.03) were detected at similar 
frequencies with both methods.  
 Microsatellite status. All primary tumours examined (n=20) showed a normal 
expression of the MLH1, MSH2 and MSH6 mismatch repair proteins  in the nucleus 
and adjacent non-neoplastic tissue elements. 
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DISCUSSION  
This study focused on the genetic characterization of liver metastases that occur 
in the context of primary colorectal carcinoma. To the best of our knowledge, this is the 
first study that compares the genetic abnormalities found in liver metastases vs. paired 
primary colorectal tumours, in which high-resolution 500K SNP arrays have been 
systematically used. Overall, primary tumours and their paired metastases from 
individual patients, frequently revealed many common chromosomal changes at both 
sites; these findings support the existence of a close genetic relationship between 
primary colorectal tumours and their paired liver metastases, as previously suggested.17 
Genetic changes observed in common in both groups of samples included gains of 
chromosomes 7, 8q, 13q and 20 and losses of the 1p, 4, 8p, 17p, 18 and 22q 
chromosomes with normal expression of the MLH1, MSH2 and MSH6 mismatch repair 
proteins. In line with other studies, all our metastatic tumours showed a higher 
frequency of these chromosomal abnormalities than primary colorectal tumors7,22 and 
some of these abnormalities, together with deletions on chromosome 15q, have been 
associated with disease progression.23 Previous studies in which the genetic 
abnormalities of colorectal carcinoma have been investigated by conventional 
cytogenetics,24 FISH,17 CGH,25 array CGH26 and low-resolution 50k SNP-arrays23 have 
also found that most of these genetic abnormalities are recurrently identified in primary 
tumours from metastatic colorectal carcinoma. Based on the high frequency of these 
chromosomal abnormalities in both primary and metastatic samples, it could be 
hypothesized that they reflect a metastatic genetic profile of colorectal carcinoma that 
could be of great clinical utility for the identification of colorectal carcinoma patients at 
higher risk of developing liver metastases, already at diagnosis.  
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Interestingly, high-level genetic amplification was found at specific regions of 
chromosomes 7, 8, 13 and 20; overall 43 genes commonly involved/altered in colorectal 
cancer and/or associated with the metastatic process, are coded in these regions. Of 
note, 17 of these 43 genes have been associated with progression of hepatocellular 
carcinomas.27-29 Altogether, these findings could suggest that these genetic 
abnormalities that are acquired by metastatic colorectal carcinoma cells in the liver 
could be associated with homing and/or adaptation to the liver microenvironment. 
Among these genes, overexpression of TWIST1 has been demonstrated to induce 
angiogenesis at the same time it has been associated with both the development of 
metastasis in hepatocellular carcinomas 30 and an unfavorable outcome in colorectal 
carcinoma patients;31 in turn, increased expression of IRS2 -commonly found in human 
hepatocellular carcinoma specimens and hepatoma cell lines -32 has been associated with 
colon tumorigenesis where it contributes to tumor progression and an aggressive clinical 
behavior.33 In line with this hypothesis, preliminary studies on genomic differences 
detected in primary colorectal carcinomas versus paired brain metastases have described 
a genetic profile consisting of gains of 8q, 12p, 12q, 20p, and loss of 5q in brain 
metastasis34 which is clearly different from that observed in our liver metastases. The 
different genetic signature associated to liver vs. brain metastases could mirror the 
unique adaptation process of metastatic tumour cells to each specific micro-
environment. Despite these findings, those three chromosomal regions which showed 
the highest levels of amplification were 13q31.3, 13q34 and 20q13.33, where four 
known cancer genes (MIRHG1, COL4A1, COL4A2 and CDH4) are coded. To the best 
of our knowledge, no specific association between amplification of these genes and 
colorectal carcinoma has been reported so far; conversely, deregulation of these genes 
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has been associated with neuroblastoma,35 esophageal squamous cell carcinoma36 and 
glioblastoma multiforme.37 
In the present study, we also show the existence of recurrent genetic changes 
between paired primary and metastatic colorectal tumour cells. Such changes mainly 
consist of 1) an increased frequency of genetic lesions of chromosomes that have been 
associated with metastatic colorectal carcinoma (1p, 7p, 8q, 13q, 17p, 18q, 20q) and, 
more interestingly, 2) acquisition of new chromosomal abnormalities (e.g. losses of 
chromosomes 4 and 10q and gains of chromosomes 5p and 6p). Interestingly, the 
former abnormalities involved chromosomal regions that encode for up to 11 genes 
which have been previously found to be involved in the metastatic process of colorectal 
carcinoma. As an example, the ANGPT2 gene (localized in chromosome 8 at 8p23.1) is 
known to be involved in angiogenic processes and has been previously associated with 
an invasive/malignant potential;38 in turn, the E2F1 gene (20q11.21) has been shown to 
play a crucial role in the control of cell cycle through down-regulation of tumor 
suppressor proteins.39 Similarly, the ID1 and BCL2L1 genes (both coded in the same 
chromosomal region at 20q11.21) are also known to play a role in cell growth, 
senescence and differentiation, and the carcinogenesis of human colorectal carcinoma,40 
while overexpression of the Id-1 protein has been associated with tumour progression in 
colorectal carcinoma.41 In turn, Paredes et al have recently described that losses of 
chromosome 17p in metastatic colorectal cancer samples cover larger regions than in 
primary tumours, suggesting that additional unknown suppressor genes could be present 
at 17p, in the newly deleted sequences.11 In line with these findings, we have recurrently 
identified loss of the MAP2K4 gene (mitogen-activated protein kinase kinase-4) at 
17p12 in the great majority of the metastatic samples analyzed. The MAP2K4 gene is a 
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member of the stress-activated protein kinase signaling cascade involved in the 
regulation of multiple cellular processes, which among other associations, has been 
recently suggested to play a functional role as a metastasis-suppressor gene in several 
malignant tumours, e.g. human prostatic cancer,42 ovarian cancer43 as well as breast and 
pancreatic tumors.44 Similarly, a potential role for 18q LOH in the development of 
colorectal cancer with associated liver metastases has been suggested,10 as well as its 
potential independent prognostic value,45 which may depend on the microsatellite 
instability status.46 In this regard, chromosomal instability has been associated in 
colorectal cancer with a worse prognosis and different groups of tumors have been 
defined based on chromosomal instability status.47 Herein, we identified loss of the 
18q22-q23 chromosomal region in the great majority (95%) of the metastatic samples 
analyzed; interestingly, no clear association could be found between 18q LOH and the 
microsatellite instability status due to normal expression of the MLH1, MSH2 and 
MSH6 mismatch repair genes and potentially also the relatively limited number of cases 
studied. Similarly, the sample size and the presence of multiple structural and/or 
numerical chromosome changes in all liver metastases analyzed precludes the study of 
chromosomal instability subtypes. 
Many patients also showed acquisition of new genetic aberrations which were 
not detected in their paired primary tumours. These included gains of chromosomes 2, 
5p, 6p, 7q and 11p and losses of chromosomes 4 and 10q. These results suggest that 
these chromosomal regions may also play a relevant role in the metastatic process as 
supported by the fact that some of them -e.g.: del(4p15.33), del(4q22.3), del(4q27), 
del(4q28.1), del(4q31), del(4q35.1) and del(10q23)- are known to contain multiple 
tumor-suppressor genes (e.g. PLK4 at 4q28.1, SFRP2 at 4q31.3, IRF2 at 4q35.1 and 
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PTEN at 10q23.2)48-51 and genes that are involved in the metastatic process.52-54 In line 
with these findings, previous studies in which primary colorectal carcinomas were 
compared with liver metastases also reported a greater frequency of chromosome 4 
losses in late vs. early stages of the disease.9,55 However, due to the limited sensitivity 
of the SNP-array technique for the detection of small clones that could already be 
present in primary tumors, further studies in which such abnormalities are investigated 
at the single cell level are required to confirm our findings.   
In summary, here we show the existence of relevant genetic differences between 
paired primary and metastatic colorectal tumours which mainly consist of 1) an 
increased frequency of genetic lesions of chromosomes that have been associated with 
metastatic colorectal cancer (1p, 7p, 8q, 13q, 17p, 18q, 20q) and, more interestingly, 2) 
acquisition of new chromosomal abnormalities (e.g. losses of chromosomes 4 and 10q 
and gains of chromosomes 5p and 6p). These genetic changes acquired by metastatic 
tumours may be associated with either the metastatic process and/or adaption of 
metastatic cells to the liver microenvironment. Further studies in larger series of patients 
in which cases with non-resecable liver metastasis are also analyzed, are necessary to 
dissect the specific role of each of the altered genes and chromosomal regions in the 
metastatic spread of colorectal tumours. Additional gene expression profile studies are 
required to validate the proteins associated with copy number alterations in the 
metastasis versus the primary tumor. 
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LEGENDS TO FIGURES 
Figure 1: Metastatic colorectal cancer genome for the 20 colorectal carcinoma patients 
genotyped on the Affymetrix 500k SNP array platform. A summary plot showing the 
frequency (panel A in the left) and fluorescence intensity log2 ratios (panel B in the left) 
of those copy number gains (plotted in red above zero values in the x-axis) and losses 
(plotted in green below zero values in the x-axis) identified in primary sporadic 
colorectal tumors (light colors) and their paired liver metastases (dark color) are 
displayed for the whole genome. The panels in the right show abnormalities identified 
in primary sporadic colorectal tumors (light colors) and their paired liver metastases 
(dark color) for individual chromosomes which showed new abnormalities in metastatic 
versus primary tumour samples (panels C to H), or displayed an increased frequency of 
abnormalities in metastatic samples which were already detected in primary tumours 
(panels I to Q). Arrows point to regions of interest. 
 
Figure 2: Metastatic colorectal cancer genome for the 20 colorectal carcinoma patients 
genotyped on the Affymetrix 500k SNP array platform; copy number changes detected 
in liver metastases (n=8/20 cases; red color) versus their paired primary tumors (blue 
color) for the 4q27, 4q28.1, 4q34.1, 5p13.1, 6p25.2 and 10q23.33 chromosomal regions 
(Panel A). Genes contained in the newly altered chromosomal regions are listed in 
italics capital letters. Log2 ratios > 0.09 and < -0.09 (shown as coloured background) 
were used as cut-off thresholds to define the presence of increased and decreased copy 
number values, respectively. All copy number changes detected between liver 
metastases versus their paired primary tumours showed statistically significant 
differences (p<0.001). As an example, the 3p14, 12q12 and 19q13 chromosomal regions 
which did not show any differences between paired primary and metastatic lesions are 
also shown (Panel B). 
 
 
